{"id":76376,"date":"2026-08-24T11:52:19","date_gmt":"2026-08-24T03:52:19","guid":{"rendered":"https:\/\/flcube.com\/?p=76376"},"modified":"2026-08-24T11:52:20","modified_gmt":"2026-08-24T03:52:20","slug":"yipinhong-wins-nmpa-clinical-trial-approval-for-category-1-urat1-inhibitor-aph03867-in-gout-and-hyperuricemia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76376","title":{"rendered":"Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Yipinhong Pharmacy Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/300723:SHE\">SHE: 300723<\/a>) announced that its <strong>Category 1 chemical drug APH03867 Tablets<\/strong> has received clinical trial approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>gout patients with hyperuricemia<\/strong>, advancing a novel oral <strong>URAT1 inhibitor<\/strong> into a market with high and growing prevalence in China.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Drug Category<\/strong><\/td><td>Category 1 chemical drug<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>APH03867 Tablets<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Gout patients with hyperuricemia<\/td><\/tr><tr><td><strong>Sponsor<\/strong><\/td><td>Yipinhong Pharmacy Co., Ltd. (SHE: 300723)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>21 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Novel <strong>oral, non-peptide small-molecule<\/strong> inhibitor of <strong>URAT1 (Urate Transporter 1)<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Inhibits URAT1 activity in the kidneys \u2192 blocks <strong>urate reabsorption in renal tubules<\/strong> \u2192 increases <strong>uric acid excretion<\/strong> \u2192 effectively lowers <strong>blood uric acid levels<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Improves <strong>hyperuricemia<\/strong> and <strong>gout symptoms<\/strong><\/li>\n\n\n\n<li><strong>Target Significance:<\/strong> URAT1 accounts for approximately <strong>90% of renal urate reabsorption<\/strong>, making it a key therapeutic target for gout and hyperuricemia<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Large Patient Base:<\/strong> China has one of the world&#8217;s largest gout and hyperuricemia populations, driven by dietary and metabolic trends, giving urate-lowering therapies a substantial addressable market.<\/li>\n\n\n\n<li><strong>Mechanistic Fit:<\/strong> As a uricosuric agent blocking ~90% of renal urate reabsorption, APH03867 offers a complementary option to xanthine oxidase inhibitors that dominate current treatment, particularly for patients with inadequate response or intolerance.<\/li>\n\n\n\n<li><strong>Category 1 Positioning:<\/strong> Category 1 status designates APH03867 as a globally novel compound, giving Yipinhong potential for differentiated intellectual property and premium positioning in a largely generic-dominated urate-lowering space.<\/li>\n\n\n\n<li><strong>Next Milestones:<\/strong> Investors will watch for first-in-human trial initiation, safety and pharmacokinetic readouts, and subsequent dose-optimization and efficacy data in hyperuricemia patients.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory timelines and commercial potential of APH03867. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements and competitive dynamics in gout and hyperuricemia therapeutics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4e00\u54c1\u7ea2\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u521b\u65b0\u836fAPH03867\u7247\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4e00\u54c1\u7ea2\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u521b\u65b0\u836fAPH03867\u7247\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-aa9e9ccb-a42b-4994-8d8f-2845efbe4a10\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4e00\u54c1\u7ea2\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u521b\u65b0\u836fAPH03867\u7247\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u4e00\u54c1\u7ea2\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u521b\u65b0\u836fAPH03867\u7247\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u4e00\u54c1\u7ea2\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u521b\u65b0\u836fAPH03867\u7247\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-aa9e9ccb-a42b-4994-8d8f-2845efbe4a10\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced that its Category 1 chemical drug APH03867 Tablets&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,1126,370],"class_list":["post-76376","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-she-300723","tag-yipinhong-pharmacy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced that its Category 1 chemical drug APH03867 Tablets has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of gout patients with hyperuricemia, advancing a novel oral URAT1 inhibitor into a market with high and growing prevalence in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76376\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia\" \/>\n<meta property=\"og:description\" content=\"Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced that its Category 1 chemical drug APH03867 Tablets has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of gout patients with hyperuricemia, advancing a novel oral URAT1 inhibitor into a market with high and growing prevalence in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76376\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-24T03:52:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-24T03:52:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76376#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76376\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia\",\"datePublished\":\"2026-08-24T03:52:19+00:00\",\"dateModified\":\"2026-08-24T03:52:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76376\"},\"wordCount\":323,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"SHE: 300723\",\"Yipinhong Pharmacy\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76376#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76376\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76376\",\"name\":\"Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-24T03:52:19+00:00\",\"dateModified\":\"2026-08-24T03:52:20+00:00\",\"description\":\"Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced that its Category 1 chemical drug APH03867 Tablets has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of gout patients with hyperuricemia, advancing a novel oral URAT1 inhibitor into a market with high and growing prevalence in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76376#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76376\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76376#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia - Insight, China&#039;s Pharmaceutical Industry","description":"Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced that its Category 1 chemical drug APH03867 Tablets has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of gout patients with hyperuricemia, advancing a novel oral URAT1 inhibitor into a market with high and growing prevalence in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76376","og_locale":"en_US","og_type":"article","og_title":"Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia","og_description":"Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced that its Category 1 chemical drug APH03867 Tablets has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of gout patients with hyperuricemia, advancing a novel oral URAT1 inhibitor into a market with high and growing prevalence in China.","og_url":"https:\/\/flcube.com\/?p=76376","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-24T03:52:19+00:00","article_modified_time":"2026-08-24T03:52:20+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76376#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76376"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia","datePublished":"2026-08-24T03:52:19+00:00","dateModified":"2026-08-24T03:52:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76376"},"wordCount":323,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","SHE: 300723","Yipinhong Pharmacy"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76376#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76376","url":"https:\/\/flcube.com\/?p=76376","name":"Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-24T03:52:19+00:00","dateModified":"2026-08-24T03:52:20+00:00","description":"Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced that its Category 1 chemical drug APH03867 Tablets has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of gout patients with hyperuricemia, advancing a novel oral URAT1 inhibitor into a market with high and growing prevalence in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76376#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76376"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76376#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76376"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76376\/revisions"}],"predecessor-version":[{"id":76378,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76376\/revisions\/76378"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}